Michael Wiederhorn
Stock Analyst at Oppenheimer
(3.70)
# 756
Out of 5,152 analysts
144
Total ratings
56.74%
Success rate
4.54%
Average return
Main Sectors:
Stocks Rated by Michael Wiederhorn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PACS PACS Group | Maintains: Outperform | $40 → $42 | $34.69 | +21.07% | 4 | Mar 4, 2026 | |
| TDOC Teladoc Health | Maintains: Outperform | $12 → $7 | $5.05 | +38.61% | 12 | Mar 3, 2026 | |
| EVH Evolent Health | Maintains: Outperform | $12 → $6 | $3.17 | +89.27% | 2 | Mar 2, 2026 | |
| CHE Chemed | Maintains: Outperform | $580 → $500 | $404.63 | +23.57% | 14 | Feb 27, 2026 | |
| UNH UnitedHealth Group | Maintains: Outperform | $415 → $385 | $285.01 | +35.08% | 18 | Jan 28, 2026 | |
| HCA HCA Healthcare | Maintains: Outperform | $500 → $540 | $532.17 | +1.47% | 13 | Jan 28, 2026 | |
| EHAB Enhabit | Upgrades: Outperform | $14 | $13.62 | +2.83% | 3 | Jan 22, 2026 | |
| GRDN Guardian Pharmacy Services | Initiates: Outperform | $30 | $33.14 | -9.47% | 1 | Oct 10, 2025 | |
| CNC Centene | Maintains: Outperform | $51 → $43 | $43.30 | -0.69% | 19 | Jul 28, 2025 | |
| HUM Humana | Maintains: Outperform | $300 → $310 | $180.18 | +72.05% | 13 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $400 → $375 | $270.96 | +38.40% | 11 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $37 | $33.09 | +11.82% | 6 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $168 | $205.51 | -18.25% | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $140 → $145 | $101.87 | +42.34% | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4.5 → $5 | $3.33 | +50.38% | 10 | Jul 25, 2024 |
PACS Group
Mar 4, 2026
Maintains: Outperform
Price Target: $40 → $42
Current: $34.69
Upside: +21.07%
Teladoc Health
Mar 3, 2026
Maintains: Outperform
Price Target: $12 → $7
Current: $5.05
Upside: +38.61%
Evolent Health
Mar 2, 2026
Maintains: Outperform
Price Target: $12 → $6
Current: $3.17
Upside: +89.27%
Chemed
Feb 27, 2026
Maintains: Outperform
Price Target: $580 → $500
Current: $404.63
Upside: +23.57%
UnitedHealth Group
Jan 28, 2026
Maintains: Outperform
Price Target: $415 → $385
Current: $285.01
Upside: +35.08%
HCA Healthcare
Jan 28, 2026
Maintains: Outperform
Price Target: $500 → $540
Current: $532.17
Upside: +1.47%
Enhabit
Jan 22, 2026
Upgrades: Outperform
Price Target: $14
Current: $13.62
Upside: +2.83%
Guardian Pharmacy Services
Oct 10, 2025
Initiates: Outperform
Price Target: $30
Current: $33.14
Upside: -9.47%
Centene
Jul 28, 2025
Maintains: Outperform
Price Target: $51 → $43
Current: $43.30
Upside: -0.69%
Humana
May 1, 2025
Maintains: Outperform
Price Target: $300 → $310
Current: $180.18
Upside: +72.05%
Jan 31, 2025
Maintains: Outperform
Price Target: $400 → $375
Current: $270.96
Upside: +38.40%
Nov 8, 2024
Maintains: Outperform
Price Target: $34 → $37
Current: $33.09
Upside: +11.82%
Oct 25, 2024
Maintains: Outperform
Price Target: $165 → $168
Current: $205.51
Upside: -18.25%
Sep 23, 2024
Maintains: Outperform
Price Target: $140 → $145
Current: $101.87
Upside: +42.34%
Jul 25, 2024
Maintains: Outperform
Price Target: $4.5 → $5
Current: $3.33
Upside: +50.38%